CFTR modulators, especially triple therapy, significantly improve sinonasal inflammation and nasal polyp size in patients with cystic fibrosis.
Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...
Joint Press Release from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and Charité - Universitätsmedizin Berlin Cell-permeable ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder. Boehringer ...
Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- ...
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
These companies offer a clear path to sustained earnings growth.
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
In cystic fibrosis, ETI significantly reduced daily cough frequency and increased physical activity levels in patients aged 12 and older.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results